April 2026 in “Actas Dermo-Sifiliográficas” Persistent chemotherapy-induced alopecia (PCIA) occurs when hair regrowth is absent or incomplete beyond 6 months after chemotherapy, with an incidence ranging from 0.9% to 43%. Drugs like busulfan and taxanes are commonly associated with PCIA, which is characterized by noninflammatory alopecia and reduced hair shaft thickness. Trichoscopic evaluation is vital for predicting hair regrowth outcomes, especially in patients on adjuvant antiestrogen therapy. Scalp cooling therapies can prevent hair loss without increasing metastatic risk, improving quality of life. Topical and low-dose oral minoxidil show promise in promoting hair regrowth, while spironolactone may also be beneficial, though not yet studied as monotherapy for PCIA. Standardizing treatment response measures with trichoscopic follow-up is crucial for managing PCIA effectively.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
9 citations
,
January 2014 in “Annals of Dermatology” Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
31 citations
,
September 2006 in “International journal of gynaecology and obstetrics” New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
June 2017 in “Reactions Weekly” Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
13 citations
,
August 1980 in “Cancer” Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
19 citations
,
June 2001 in “Annals of Internal Medicine” Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
5 citations
,
August 2012 in “Journal of Dermatology” Tamoxifen may cause female hair loss by increasing androgen receptor expression.
February 2024 in “PloS one” Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
3 citations
,
July 2014 in “Indian Journal of Surgery” Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
November 2025 in “Frontiers in Endocrinology” Apigenin and ellagic acid may help manage PCOS symptoms.
7 citations
,
October 2019 in “Klinická onkologie” Cancer treatments often cause hair loss and damage, affecting patients' mental health.
403 citations
,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
1 citations
,
June 2001 in “Annals of Internal Medicine” The document concludes that there is no credible evidence that distant healing works, and it should not be further studied in medical literature.
January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
January 2008 in “Journal für Kardiologie (Krause & Pachernegg GmbH)” Healthy aging can be promoted through physical activity, lifestyle changes, and certain treatments.
658 citations
,
June 2003 in “Endocrine reviews” Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.
68 citations
,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
53 citations
,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
February 2026 in “International Journal of Molecular Sciences” Combining hyperthermia with natural compounds and conventional treatments improves cancer therapy effectiveness and reduces side effects.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
January 2026 in “Therapeutics” SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
1 citations
,
January 2018 in “Springer eBooks” The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
215 citations
,
March 2011 in “Clinical Cancer Research” Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
Certain drugs can worsen hair loss in people prone to androgenetic alopecia.